


LUNG MACRODISSECT AI

HALO Macrodissect Solutions




Lung Macrodissect AI harnesses the power of AI to quantify tumor content and facilitate downstream molecular testing in cases of NSCLC.


powered by **indica** labs

MACRODISSECTION REINVENTED


Lung Macrodissect AI is an AI-powered tool that quantifies tumor content and guides ROI selection to enhance macrodissection workflows and downstream molecular analysis in cases of non-small cell lung cancer.



H&E



Tumor Content Heatmap



Heatmap with Annotation

File Format Compatibility

- + Non-proprietary (JPG, TIF, OME, TIFF, DICOM [DCM*])
- + Leica (SVS, AFI, SCN, LIF)
- + Hamamatsu (NDPI, NDPIS)
- + Philips (iSyntax, i2Syntax)
- + 3DHistech (MRXS)
- + Nikon (ND2)
- + Akoya (QTIFF, component TIFF)
- + Olympus / Evident (VSI)
- + Zeiss (CZI)
- + Ventana (BIF)
- + KFBIO (KFB, KBBF)

*whole slide images

Inputs

- + H&E whole slide images from primary and metastatic NSCLC resections, excisions, and/or core needle biopsies


Key Output Metrics

- + Tumor density heatmap
- + Total cell count
- + Tumor cell count
- + Percent tumor content for whole slide image and ROIs



INCREASE QUALITY

Lung Macrodissect AI reliably quantifies tumor content for downstream molecular analysis, ensuring the quality of downstream test results.



STREAMLINE WORKFLOWS AND SAVE RESOURCES

With automated tumor content analysis, you can streamline your ROI selection process and save time.



AUDITABLE PROCESS

Create an auditable macrodissection workflow, ensuring transparency and efficiency.


CLINICAL VALIDATION

Lung Macrodissect AI was validated on the Leica Aperio GT 450 (SVS format).

Experiment: 317 externally sourced primary and metastatic non-small cell lung cancer H&E images previously unseen by the algorithm were assessed for tumor content by five pathologists. After a four-week washout period, the five pathologists reviewed the same slides again, this time with the assistance of Lung Macrodissect AI. They had the option to agree with the algorithm's analysis or provide their own tumor content estimations.


The intraclass correlation coefficient (ICC) was calculated using continuous tumor content data and Fleiss' kappa was calculated after samples were dichotomized based on a 20% tumor content cut-off, a minimum requirement for most molecular tests. Both ICC and Fleiss' kappa were measured before and after assistance from Lung Macrodissect AI.

Inter-Pathologist Agreement of Tumor Content
Estimation With and Without Lung
Macrodissect AI




Results: Lung Macrodissect AI significantly increased the consistency and agreement of inter-pathologist tumor content reporting, demonstrating the algorithm's ability to accurately quantify tumor content, standardize macrodissection workflows, and reduce the number of inadequately concentrated tests sent for downstream analysis.


A FULLY-AUTOMATED LUNG MACRODISSECT AI WORKFLOW



Lung Macrodissect AI analyzes tumor content



Pathologist annotates regions of tumor



Annotations are modified for macrodissection platform




Automated tissue macrodissection

Lung Macrodissect AI can be coupled with the Tisector automated macrodissection platform from Xyall, creating an all-in-one solution that is auditable, accurate, and precise, saving staff time and resources.


HALO Macrodissection Solutions

CRC Macrodissect AI



Reliable tumor content analysis for colorectal carcinoma specimens.

Breast Macrodissect AI



Reliable tumor content analysis for breast carcinoma specimens.



Ready to learn more?

Contact us to schedule a demo of Lung Macrodissect AI and HALO AP®.

info@indicalab.com | emea@indicalab.com | japan@indicalab.com | china@indicalab.com
USA +1 505 492-0979 | UK/EU +44 0 333 090 1113 | 日本 +81 (0)3 4400 0466 | 中国 +86 13761896143

Lung Macrodissect AI is not a medical device in the EU/UK and is not intended to be used for diagnostic purposes. Lung Macrodissect AI is accessed via the HALO AP® enterprise digital pathology platform. Lung Macrodissect AI is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use.

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.

indica labs